Table 3 Prognostic factors of overall survival, disease free survival and local control among the 48 extramedullary plasmacytoma patients

Gender (Male vs Female)

0.382

2.287

0.358–14.613

0.940

0.953

0.276–3.297

Age, years (<50 vs ≧ 50)

0.375

2.282

0.369–14.112

0.752

1.216

0.362–4.085

Lymph node metastasis (Without vs With)

0.019

10.335

1.463–72.986

0.048

4.279

1.014–18.052

Size of primary tumor (<5 cm vs ≧5 cm)

0.026

18.612

1.416–244.713

0.004

7.496

1.903–29.534

Number of primary tumors (Solitary vs Sporadic)

0.480

2.223

0.242–20.455

0.723

0.770

0.182–5.074

Treatment (Single vs Combined)

0.650

0.728

0.185–2.872

0.910

0.940

0.321–2.754

Anatomic Location (HN vs Others)

0.306

2.096

0.508–8.647

0.988

1.008

0.356–2.856

Gender (Male vs Female)

0.378

2.276

0.364–14.230

0.990

1.008

0. 300–3.388

Age, years (<50 vs ≧ 50)

0.411

2. 049

0.371–11.311

0.807

1.159

0.354–3.799

Clinical stage (I vs II vs III)

0.001

13.030

2.812–60.382

<0.001

5. 795

2.245–14.958

Number of primary tumors (Solitary vs Sporadic)

0.472

2.248

0.247–20.461

0.746

0.791

0.191–3.272

Treatment (Single vs Combined)

0.680

0.680

0.190–2.957

0.982

0.988

0.342–2.851

Anatomic location (HN vs Others)

0.291

2.291

0.521–8.842

0.951

1.033

0.365–2.924